8-K current report · filed Aug 6, 2026

Insmed Incorporated (INSM) 8-K Current Report: August 6, 2026

Item 2.02Item EX-99.1Item EX-99.2INSM overview

Short answer

Insmed Incorporated (INSM) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Q2 2026 financial results for quarter ended June 30, 2026 announced August 6, 2026.

Insmed Incorporated 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 financial results for quarter ended June 30, 2026 announced August 6, 2026
  • Press release contains the detailed financial results and management commentary
  • Investor conference-call slides included as Exhibit 99.2 for additional operating context

Item EX-99.1 · Exhibit EX-99.1

  • Q2 2026 revenue $425.5M, up 296% year over year, driven by BRINSUPRI launch revenue of $309.2M
  • BRINSUPRI guidance raised to $1.25B-$1.40B from at least $1B, signaling stronger-than-expected launch demand
  • ARIKAYCE revenue $116.3M, up 8% year over year, with international growth of 19% partly offsetting U.S. growth of 2%
  • Net loss narrowed to $13.2M from $321.7M, despite R&D of $210M and SG&A of $247.5M supporting pipeline and commercialization
  • Peak revenue estimate raised above $14B across BRINSUPRI, TPIP, and ARIKAYCE; TPIP Phase 3 execution remains a key valuation catalyst

Item EX-99.2 · Exhibit EX-99.2

  • Q2 revenue $425.5M, up from $107.4M, driven by BRINSUPRI launch contribution and ARIKAYCE growth
  • BRINSUPRI Q2 revenue $309.2M, supporting raised 2026 guidance to $1.25B-$1.4B from previously greater than $1B
  • ARIKAYCE Q2 revenue $116.3M, up 8.3% year over year, with U.S. label expansion filing completed
  • Cash, equivalents and marketable securities approximately $1.2B at June 30, 2026, with cash-flow positivity targeted for 2027 without additional capital
  • TPIP 12-month PAH data showed 55-meter 6MWD improvement, approximately 60% NT-proBNP reduction and approximately 80% achieving WHO functional class I or II

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Insmed Incorporated 8-K filings

Get the next INSM 8-K as it lands

Follow INSM for push alerts, or ask the research agent what this filing means.